This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baz, M.
Right arrow Articles by Boivin, G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baz, M.
Right arrow Articles by Boivin, G.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 2009, p. 791-793, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.01276-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Activity of the Oral Neuraminidase Inhibitor A-322278 against the Oseltamivir-Resistant H274Y (A/H1N1) Influenza Virus Mutant in Mice{triangledown}

Mariana Baz, Yacine Abed, Benjamin Nehmé, and Guy Boivin*

Research Center in Infectious Diseases, CHUQ-CHUL, and Laval University, Québec City, Québec, Canada

Received 23 September 2008/ Returned for modification 15 October 2008/ Accepted 12 November 2008

The new oral neuraminidase (NA) inhibitor A-322278 was evaluated in mice infected with influenza A/H1N1 wild-type virus or the oseltamivir-resistant (H274Y mutant) virus. A-322278 decreased mortality rates and lung virus titers significantly more than oseltamivir in mice infected with the NA H274Y mutant when therapy was started 4 h before or even 48 h after infection.

* Corresponding author. Mailing address: CHUQ-CHUL, room RC-709, 2705 Blvd. Laurier, Sainte-Foy, Québec, Canada G1V 4G2. Phone: (418) 654-2705. Fax: (418) 654-2715. E-mail: Guy.Boivin{at}crchul.ulaval.ca

{triangledown} Published ahead of print on 17 November 2008.

Antimicrobial Agents and Chemotherapy, February 2009, p. 791-793, Vol. 53, No. 2
0066-4804/09/$08.00+0     doi:10.1128/AAC.01276-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • McSharry, J. J., Weng, Q., Brown, A., Kulawy, R., Drusano, G. L. (2009). Prediction of the Pharmacodynamically Linked Variable of Oseltamivir Carboxylate for Influenza A Virus Using an In Vitro Hollow-Fiber Infection Model System. Antimicrob. Agents Chemother. 53: 2375-2381 [Abstract] [Full Text]  
  • Weinstock, D. M., Zuccotti, G. (2009). The Evolution of Influenza Resistance and Treatment. JAMA 301: 1066-1069 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»